Oncolytic Virus Therapy Landscape Expands with Over 100 Companies Leading the Charge in Pioneering New Treatments.

DelveInsight's Oncolytic Virus Competitive Landscape 2026 report highlights a robust oncolytic virus pipeline with 100+ active players developing 110+ drugs. Key companies such as Oncolytics Biotech, SillaJen, Candel Therapeutics, and others are evaluating new oncolytic virus drugs. Promising therapies like Pelareorep, Pexa-Vec, and CAN-2409 are in different phases of clinical trials. The market is driven by growing cancer incidence, increasing understanding of cancer biology, advancements in viral engineering, and rising adoption of personalized medicine.